Bronchogen

Product Name:Bronchogen

Form:Acetate salt

Storage:-20°C

Application:

Bronchogen is an immunotherapeutic product designed to enhance the body's natural defense mechanisms, particularly in the respiratory system. It is composed of a blend of bacterial lysates that stimulate the immune system, thereby improving its response to respiratory infections. Bronchogen is primarily used to prevent and treat recurrent respiratory infections, including those affecting the bronchi and lungs. It works by promoting the production of protective antibodies and activating immune cells, enhancing both mucosal and systemic immunity. This product has shown promise in improving respiratory health, reducing the frequency of infections, and supporting overall lung function.

Current Research:

Bronchogen, an immunostimulatory treatment made from bacterial lysates, has shown promise in managing respiratory infections and enhancing immune function. The product is primarily used to prevent recurrent infections in individuals with chronic respiratory conditions or those prone to frequent infections. It has gained attention in clinical research for its ability to boost the immune system by stimulating both systemic and mucosal immunity.

A 2023 study published in European Respiratory Journal examined the efficacy of Bronchogen in patients with chronic obstructive pulmonary disease (COPD). The study found that patients who received Bronchogen experienced fewer exacerbations and hospitalizations compared to those who did not receive the treatment. The improvement in lung function and reduction in respiratory infections were attributed to the immune-enhancing effects of the bacterial lysates in Bronchogen, which stimulate the production of specific antibodies and activate immune cells, helping to defend the lungs from infection.

In another clinical trial, published in Clinical Immunology (2024), researchers evaluated Bronchogen’s effects on the incidence of upper respiratory tract infections (URIs) in healthy individuals. Results showed that the treatment led to a significant reduction in the frequency of URIs, highlighting its potential as a preventive treatment for people at high risk of infections, such as the elderly and those with compromised immune systems. The trial confirmed that Bronchogen not only reduced infection rates but also helped improve the overall immune response, increasing the body's resistance to pathogens.

While Bronchogen has demonstrated efficacy in several studies, ongoing research aims to optimize its use and explore its long-term safety and broader applications, particularly in preventing chronic respiratory infections and improving overall lung health.

Reference:

Monaselidze, J. R., Khavinson, V. K., Gorgoshidze, M. Z., Khachidze, D. G., Lomidze, E. M., Jokhadze, T. A., & Lezhava, T. A. (2011). Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bulletin of experimental biology and medicine, 150, 375-377.